GLUD1 for Duchenne: Restoring Muscle Function
Novel Metabolic Approach Shows Promise for Duchenne Muscular Dystrophy Treatment
Table of Contents
Researchers Discover Therapeutic Potential in Targeting Glutamate Metabolism
Leuven, Belgium – A groundbreaking study from researchers at VIB-KU Leuven has unveiled a novel therapeutic strategy for Duchenne Muscular Dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration and weakness. The examination focused on targeting glutamate metabolism, a critical cellular process, using a specific inhibitor known as R162. The findings, published in the American Journal of Pathology, demonstrate significant improvements in muscle function and regeneration in preclinical models of DMD.
Enhancing Muscle Strength and Coordination
In a preclinical study utilizing the mdx mouse model, a widely accepted model for studying DMD, systemic administration of R162 yielded remarkable results. Researchers observed a significant enhancement in muscle strength and coordination in the treated mice.This functional recovery was attributed to a multi-faceted mechanism involving reduced muscle damage, an improved myogenic potential of satellite cells – the muscle stem cells responsible for repair – and the restoration of neuromuscular junction (NMJ) structure and function.Emanuele Berardi, phd, a co-lead investigator from the Laboratory of Tumor Inflammation and Angiogenesis at VIB-KU Leuven and the Tissue Engineering lab at KU Leuven, elaborated on the findings.”This functional recovery was linked to reduced muscle damage, enhanced myogenic potential of satellite cells, and restoration of neuromuscular junction (NMJ) structure and function,” Dr. Berardi stated. “Interestingly, while GLUD1 inhibition in macrophages alone promoted satellite cell activation, it was not sufficient to restore muscle function, highlighting the essential but not standalone role of macrophages in muscle regeneration. we further demonstrated that macrophages are required to mediate the full therapeutic effect of R162,especially in supporting NMJ remodeling.”
Reprogramming Glutamate Metabolism for Muscle Repair
The study further elucidated the mechanistic underpinnings of R162’s therapeutic effects. Andreia Pereira-Nunes, PhD, a co-investigator from VIB-KU leuven and the Life and Health Sciences Research Institute (ICVS) in Braga, Portugal, explained, “Mechanistically, R162 treatment reprogrammed glutamate metabolism in dystrophic muscles, boosting local glutamate availability, which in turn enhanced NMJ morphological reorganization and restored acetylcholine levels.” acetylcholine is a crucial neurotransmitter for muscle function.
Crucially, the treatment was found to be well-tolerated in the animal models, with no adverse effects observed on body weight, food intake, or general behavior, suggesting a favorable safety profile.
A Promising Non-Steroidal Therapeutic Avenue
This research introduces a novel, non-steroidal therapeutic approach that bypasses the genetic defect inherent in DMD. Instead, it focuses on enhancing neuromuscular function through metabolic reprogramming. The dual action of R162, which supports both muscle precursor cell (satellite cell) function and neurotransmission, presents a promising and potentially translatable strategy for improving patient outcomes. Its demonstrated efficacy and safety in dystrophic mice underscore its potential for clinical application.
Ummi Ammarah, a PhD candidate and co-investigator from VIB-KU Leuven and the Molecular Biotechnology Center at the University of Turin, Italy, concluded, “Our results provide the first proof-of-concept that metabolic drugs can be effectively used to treat muscular dystrophies, offering a novel strategy by bypassing the genetic defect and modifying a non-muscle-related function.”
this pioneering work opens new avenues for therapeutic progress in DMD, offering hope for a more effective and safer treatment paradigm by targeting essential metabolic pathways essential for muscle health and function.
Source:
PEREIRA-NUNES, A. et al. (2025). Pharmacologic Inhibition of Glutamate Dehydrogenase 1 Improves Functional Recovery of Neuromuscular Junctions and Muscle Function in Duchenne Muscular Dystrophy.The American Journal of Pathology. doi.org/10.1016/j.ajpath.2025.05.003.